Drafting a Vaccine Clinical Development Plan (CDP) for Clear, Decision-Ready Progression

Free Webinar for Biotech, Pharma, and Global Health Innovators

A vaccine Clinical Development Plan (CDP) is a decision-ready roadmap that connects clinical questions, program decisions, and evidence needs across phases. When CDP assumptions aren’t aligned early, teams can lose time to avoidable rework, evidence gaps, and late-stage amendments.

In this CPIVC webinar series session featuring P95 speakers, you’ll learn practical approaches to structuring a CDP that stays usable as vaccine programs evolve, supported by RSV/Zoster examples and live discussion.

Drafting a CDP Webinar: What You’ll Learn

• What belongs in a CDP and how to structure it for real decision-making

• How to connect development objectives to study design choices across phases

• Practical case examples (RSV / Zoster) illustrating CDP logic in action

• How to anticipate evidence needs that can affect later-stage plans

• Panel discussion and live Q&A with vaccine development leaders

Webinar Details

• Date: Thursday, March 5, 2026
• Time: 15:00-16:45 BJT / 08:00-9:45 CET
• Location: Online via Zoom
• Includes: Live Q&A with speakers and panelists

Meet The Speakers And Panelists

Laurence De Moerlooze serves as Chief Medical Officer at P95, drawing on more than two decades of experience in vaccine R&D and clinical leadership. She began her career at GSK Biologicals, where over 15 years she played a central role in regulatory, medical, and strategic functions, contributing to the development of several high-impact vaccines, including one targeting HPV. Her work later expanded at Takeda, where she led global vaccine programs focused on Zika and Norovirus. Before joining P95, Laurence spent four years as Executive Vice President and CMO at Bavarian Nordic, guiding the company’s clinical pipeline across infectious disease areas. She holds a PhD in Virology from the University of Liège and completed postdoctoral research in Canada, the UK, and Belgium.

Adriana Bastidas is an experienced vaccine and drug safety physician with a proven track record in various pharmaceutical companies for more than 17 years, including GlaxoSmithKline Vaccines, Mithra Pharmaceuticals, CureVac and Bavarian Nordic. At GSK, she worked as safety physician and medical, leading teams of medical monitors and medical data reviewers for vaccine development programs. During her time at GSK, she drove the successful implementation of phase 1 to 3 clinical trials and supported 2 successful new product license applications.

Dr. Haiwen Tang graduated from Shanghai 2nd Medical University and ever worked as an internal medicine physician at Ruijin Hospital in Shanghai. He obtained Ph.D. in Immunology from the University of Paris VII in France in 1993 and then went to the University of Missouri in the United States to continue his research on the pathogenesis of immune diseases. From 1998 to 2023, he worked at GSK Vaccines. He once served as the medical director in North Asia and the vice – president of intercontinental medical affairs. He organized and participated in multiple vaccine clinical trials carried out in Asia, including those for the combined measles, rubella, and mumps vaccine, acellular DPT, hepatitis B, inactivated polio, hexavalent vaccine against Haemophilus influenzae type b, cervical cancer vaccine, rotavirus vaccine, influenza pandemic vaccine, varicella – zoster vaccine, and RSV vaccine, as well as epidemiological surveys. He has published more than 40 papers in academic journals such as Vaccine and the American Journal of Immunology.

Mr. Jinbo Gou is the Vice President of CanSino Biologics, the head of the Clinical Operations Center, as well as researcher. He has nearly 20 years of experience in the fields of public health and vaccine research. He has been engaged in infectious disease control and epidemiological research at National CDC and Tianjin CDC. He established the clinical department at CanSino Biologics and has led the team to carry out domestic and international clinical development of multiple innovative products such as meningococcal, DPT, pneumococcal, COVID – 19, polio, and tuberculosis vaccines over the years, managing nearly 80 clinical studies. He has participated in communication and exchanges with domestic and international drug regulatory agencies and the WHO for many times and supported product registration. He has undertaken multiple provincial – and ministerial – level key R & D projects and has published more than 20 research papers in journals such as The Lancet, Vaccine, Journal of Infection, and EMI. He serves as a member of the Vaccine Clinical Research Branch of the Chinese Preventive Medicine Association, the Clinical Research Branch of the China Association for Vaccines, the Enterovirus Disease Branch, the vice – chairman of the Vaccine Professional Committee of the Guangdong Respiratory and Health Society, and an expert in the review of Tianjin science and technology projects. He has won several awards such as the 131 Talents, Innovative Talents, and Outstanding Scientific and Technological Talents, as well as the Tianjin May 1st Labor Medal.

Yuan Yuan, Secretary General of CPIVC, has been working at PATH since January 2007, serving as Project Assistant, Project Administrator, Project Manager and Alliance Manager. She is currently the Country Representative in China, responsible for PATH’s commercial and business development in China. During the 18 years of working in the vaccine field, he participated in WHO precertification of JE vaccine, rotavirus vaccine development, pneumonia conjugate vaccine development and training, OPV overseas clinical practice, Sabin IPV D antigen international standard development, HPV vaccine precertification and other projects. Familiar with vaccine life cycle production, quality, clinical, drug administration, pharmacovigilance, biosafety and other aspects. Prior to joining PATH, she was a project manager at Integrity Metals in Singapore and worked in Indonesia.

Ms. Yun Ji has a clinical medicine background and a Doctor of Business Administration (DBA) from Belhaven University in the United States. Since entering the field of pharmaceutical R & D in 2004, she has 21 years of relevant experience in clinical research. She served continuously for 15 years at the China R & D Center of Merck & Co., Inc. (MSD), responsible for global clinical research data management, clinical operations, and related work, as well as team management. She worked for 5 years at a domestic CRO company, responsible for building system as well as establishment of the clinical operations and data management teams, leading and guiding the team to participate in domestic and overseas therapeutic and preventive vaccine clinical research projects.

Who Should Attend

• Clinical development leaders building or updating vaccine development strategy
• Biotech and vaccine sponsors preparing end-to-end evidence plans (early to late phase)
• Clinical operations and program management teams translating strategy into executable study plans
• Medical, safety, epidemiology, and biometrics leaders contributing to CDP assumptions and evidence needs
• Regulatory affairs and submission teams aligning CDP outputs with regulatory-facing documentation
• Alliance partners and cross-functional stakeholders who need shared alignment on program decisions and timelines